Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;29(4):212-5.
doi: 10.1097/YIC.0000000000000029.

Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia

Pavel Golubchik  1 , Jonathan Sever, Abraham Weizman
Affiliations

Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia

Pavel Golubchik et al. Int Clin Psychopharmacol. 2014 Jul.

Abstract

The aim of this study was to assess the response of social phobia (SP) symptoms to methylphenidate (MPH) treatment in children with attention deficit hyperactivity disorder (ADHD). Twenty-one ADHD patients with SP, aged between 8 and 18 years, received 12 weeks of MPH treatment. The severity of SP symptoms were assessed by the Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA), and the severity of ADHD symptoms was assessed by the ADHD Rating Scale at baseline and at endpoint. MPH treatment was associated with a significant decrease in the ADHD Rating Scale scores (P<0.0001) and in the total LSAS-CA scores (P=0.013), as well as the school-related items of LSAS-CA (P=0.011). A significant correlation was found between the reductions in ADHD score and total LSAS-CA score (P=0.038), especially in school-related SP. The improvement in ADHD symptoms because of MPH treatment correlates with a parallel improvement in SP. MPH treatment appears to be safe and effective in ADHD/SP children.

PubMed Disclaimer

References

    1. Abikoff H, Mcgough J, Vitiello B, Mccracken J, Davies M, Walkup J, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders.J Am Acad Child Adolesc Psychiatry 2005;44:418–427 - PubMed
    1. Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.Depress Anxiety 2009;26:212–221 - PubMed
    1. Bedard AC, Tannock R.Anxiety, methylphenidate response, and working memory in children with ADHD.J Atten Disord 2008;11:546–557 - PubMed
    1. Biederman J, Newcorn J, Sprich S.Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders.Am J Psychiatry 1991;148:564–577 - PubMed
    1. Campbell-Meiklejohn DK, Simonsen A, Jensen M, Wohlert V, Gjerloff T, Scheel-Kruger J, et al. Modulation of social influence by methylphenidate.Neuropsychopharmacology 2012;37:1517–1525 - PMC - PubMed

MeSH terms

Substances